

Research & Development in the Developing World

Almost two-thirds of the world's people who are infected with HIV live in sub-Saharan Africa, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). Other chronic diseases, including tuberculosis (TB) and malaria, often afflict HIV-infected patients in this region.

The annual spending on health needs in most of these countries is approximately \$5 U.S. per person per year. In these and other developing countries, treatments for HIV and opportunistic infections (infections that occur because of a weakened immune system) are often beyond what public health systems and most individuals can afford.

As a member of the global health care community, Johnson & Johnson and its operating companies are working to improve access to health care for people in the developing world. These efforts include research and development to find effective diagnostics and treatments, and ways to deliver them where they are needed most. Here are some examples of programs our companies support:

- In 2009, we announced a unique collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Janssen Pharmaceutica NV, an affiliate of Tibotec. The collaboration responds to the urgent need to accelerate the discovery and development of new drugs to fight TB. The two organizations will share their expertise and resources in the development of TMC207, which could become the first TB drug with a new mechanism of action in 40 years. The collaboration will maximize the expertise and resources from both the public and private sectors with the intent to improve the treatment of one of the world's oldest and most deadly diseases. The Tibotec Pharmaceuticals Ltd. initiative Research and Education in HIV/AIDS for Resource- Poor Countries (REACH) is providing funds for projects in which organizations in the developed and developing world collaborate to enhance HIV/AIDS treatment and care. Projects support research and education in Africa, Asia, Latin America and Eastern Europe. Learn more at www.tibotec.com/bgdisplay.jhtml?itemname=dw_leftblock2.
- Tibotec is working with the nonprofit product development partnership, International Partnership for Microbicides (IPM), to develop a microbicide treatment to help women prevent sexual transmission of HIV. As part of the TMC120 Microbicide Collaboration, Tibotec gave IPM a royalty-free license for an anti-HIV compound it discovered. The license enables IPM to develop, manufacture and distribute a vaginal microbicide in resource-poor countries. This agreement marked the first collaboration in the microbicide field between a major health care company and a non-profit product development partnership such as IPM. Learn more at www.tibotec.com/bgdisplay.jhtml?itemname=dw_rightblock1.

- Virco BVBA is collaborating with world health agencies, including the World Health Organization and UNAIDS, to advance our understanding of how the HIV pandemic has evolved and to monitor the emergence of HIV drug resistance. Learn more by visiting www.vircolab.com.
- Tibotec is developing an innovative treatment for drug-resistant tuberculosis and currently has clinical trials underway in South Africa, with additional trials planned for other developing countries. Learn more at www.tibotec.com/bgdisplay.jhtml?itemname=TB_disease.